Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period ...
September 23, 2011 (London, United Kingdom) — Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban (Xarelto, Bayer) in Europe. The EMA's ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Dear Dr. Roach: I am an 81-year-old female who has been on Xarelto for years due to my deep vein thrombosis (DVT). I also have an inferior vena cava (IVC) filter. I read that low-dose aspirin (325 mg) ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous ...
MedPage Today on MSN
Apixaban snags a win in head-to-head trial of direct oral anticoagulants
Favorable safety shown in secondary prevention for acute venous thromboembolism ...
NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results